I have no position on MNKD, but would like to. My concern is that it looks as though Afrezza is following the same path that Exubera went. Yes Afrezza is smaller, and from what I read is taken up faster than Exhubera, but if inhaling insulin is supposed to be this holy grail, then Exubera should have made some impact on the market. I have a hard time thinking that being smaller and taking up faster is going to make this huge difference in the market. If you really hate needles, does using a bong like thing or having to wait a little longer make that much of a difference. It seems that this long term uncertainty lung effect weighed heavily on Exhubera's adoption and would have the same effect on Afrezza. Why wouldn't have Pfizer just tried to make a smaller bong or research better means for it to be taken up faster? Just some concerns and questions.